Channelchek - Looking for the next apple? This is the orchard.

ZOMDF

$0.09

(2.65%)

FLWS

$4.04

(3.19%)

ACCO

$4.16

(4.79%)

ARLP

$24.59

(0.1%)

AUIAF

$0.15

(1.87%)

AZZ

$151.58

(0.74%)

BTBT

$1.46

(-7.59%)

BTM

$0.49

(0%)

CVKD

$2.35

(0%)

LCE:CA

$0.25

(0%)

COCP

$0.95

(-0.73%)

CDRO

$9.48

(-1.09%)

CVGI

$4.66

(-2.71%)

LODE

$3.9

(-6.13%)

CMTL

$1.67

(-4.86%)

CNDT

$1.57

(3.62%)

CXW

$30.69

(-1.29%)

CMLS

$0.01

(0%)

DRCT

$2.46

(-4.65%)

DLHC

$5.65

(5.02%)

SSP

$3.12

(0.94%)

ELDN

$3.83

(-4.6%)

EVC

$10.3

(-6.96%)

EDRY

$22.74

(-1.09%)

ESEA

$71.51

(0.08%)

FAT

$0.16

(0%)

RAIL

$7.71

(-3.14%)

GDEV

$11.7

(0%)

GOVX

$0.88

(-13.31%)

GOCO

$0.3

(0%)

GHM

$107.83

(-2.15%)

GLDD

$17

(0%)

GYRE

$7.58

(-1.88%)

HMENF

$1.85

(-2.12%)

III

$4.07

(2.39%)

IPOOF

$10.39

(-2.53%)

KELYA

$15.41

(7.54%)

KTOS

$46.51

(-6.38%)

LUCK

$7.33

(1.88%)

MAIA

$1.34

(-8.5%)

MGROF

$0.26

(0%)

NTRB

$3.13

(2.62%)

OCGN

$1.36

(-4.55%)

PERF

$1.92

(0%)

QMCI

$0.15

(0%)

RGP

$4.79

(4.25%)

SGA

$9.19

(-0.81%)

SHWZ

(0%)

SHIP

$14.82

(-2.69%)

SLQT

$0.72

(-3.42%)

SKYX

$1.19

(-5.2%)

SNAL

$5.21

(4.83%)

GEO

$29.73

(-0.32%)

ODP

$28

(0%)

TNXP

$11.67

(0.51%)

TSQ

$6.71

(-1.03%)

TZOO

$11.09

(0.05%)

UNCY

$5.05

(0.6%)

VVX

$75.21

(-0.58%)

VNCE

$6.28

(1.95%)

XELB

$1.42

(-4.39%)

ZOMDF

$0.09

(2.65%)

FLWS

$4.04

(3.19%)

channelchek-in

‌

7/16/2026

Eli Lilly Pays $3.8 Billion for AtaiBeckley as Big Pharma’s Push Into Mental Health Enters a New Phase

The pharmaceutical industry’s appetite for neuroscience innovation just produced one of the most significant mental health deals in years. Eli Lilly (NYSE: LLY) announced Wednesday it has entered into a definitive agreement to acquire AtaiBeckley (Nasdaq: ATAI), a clinical-stage biopharmaceutical company developing rapid-acting therapies for treatment-resistant depression and other serious mental health conditions. The deal values AtaiBeckley at approximately $2.8 billion in upfront equity consideration, with an additional $1.0 billion in potential milestone-based contingent value rights, bringing the total potential transaction value to approximately $3.8 billion.

3 min read